Newron Pharmaceuticals SpA has reported positive six-month data for its selective sodium channel blocker, evenamide, as an add-on therapy to antipsychotic drugs in chronic, treatment-resistant schizophrenia. Patients who had responded at the initial six-week evaluation showed continued improvements in symptoms of psychosis, while others who had not responded at six weeks did so by six months.